New FDA/USDA Report Looks At Ways To Prevent Listeria Contamination
redOrbit Staff & Wire Reports – Your Universe Online Stricter control of temperature while refrigerating food, keeping food contact surfaces clean and sanitary, and wearing gloves while serving customers could help prevent the spread of...
Latest Gram positive bacteria Stories
TRU-D No. 6 and 7 mark largest deployment within a single hospital network ALLENTOWN, Pa., May 21, 2013 /PRNewswire/ -- Lehigh Valley Health Network has announced the deployment of two additional TRU-D SmartUVC(TM) devices, adding to its existing arsenal of five 5-foot-5 germ-killing UV disinfection robots. With seven devices taking up residence within the network, LVHN is now deploying the largest fleet of TRU-Ds in the U.S. to proactively combat superbugs and provide the best...
SAN DIEGO, May 17, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), supporting the development of novel human antibody therapeutics to combat Staphylococcus aureus (S. aureus or Staph) infections, including...
ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and summarized operational highlights. Operational Highlights Emphasis on C. difficile (C. diff) Infection Prevention (SYN-004) In the U.S. each year, 24 million patients are administered IV antibiotics([1]) which may be...
Certain types of anti-depressants have been linked to an increase in the risk of Clostridium difficile infection (CDI) finds a study in BioMed Central's open access journal BMC Medicine. Awareness of this link should improve identification and early treatment of CDI. CDI is one of the most common hospital acquired infections and is responsible for more than 7000 deaths annually in the USA alone. Several types of medications are thought to increase risk of CDI, including anti-depressants,...
ROSEVILLE, Minn., May 1, 2013 /PRNewswire/ -- William "Bill" McGuire, M.D., former chairman and CEO of UnitedHealth Group, has joined the board of directors of Rebiotix Inc. The Roseville, Minn.-based biotechnology company is pioneering a practical and non-antibiotic treatment for recurrent Clostridium difficile infection (CDI) known as Microbiota Restoration Therapy (MRT). CDI has been linked to 14,000 deaths annually in the US, and has become the most common healthcare-associated...
Growing Competition Among Highly Effective Therapies Will Likely Constrain Uptake of Emerging Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., April 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European infectious disease specialists agree that effect on recurrence rate is one of the drug attributes that most influences their...
NEW YORK, April 29, 2013 /PRNewswire/ -- Anterios, Inc., a privately held aesthetic medicine and medical dermatology biopharmaceutical company, announced today that CEO and Founder, Jon Edelson, MD will be presenting at Needham & Company's 12(th) Annual Healthcare Conference in New York City on April 30, 2013. Dr. Edelson will be joining a roster of presenters that includes senior management from some of the most well respected public and private companies in the Biotechnology,...
Specialised Therapeutics Australia to Launch DIFICID May 14, 2013 JERSEY CITY, N.J., April 26, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Therapeutic Goods Administration, the Australian regulatory body for therapeutic goods such as medicines, has approved DIFICID® (fidaxomicin) tablets for the treatment of confirmed Clostridium difficile infection (CDI) in adults. DIFICID will be available to patients in Australia starting May 14,...
CHESTERBROOK, Pa., April 25, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the first quarter 2013 on Monday, April 29, 2013 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 8:30 a.m. ET to discuss results and highlights of the first quarter. The presentation slides to be used during the call will be available on the "For Investors" section...
EXTON, Pa., April 22, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM), an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections (CDI). CDI is a common and dangerous gastrointestinal...
Latest Gram positive bacteria Reference Libraries
Streptococcus salivarius is a species of spherical, Gram-positive bacteria which colonize the mouth and upper respiratory tract of humans a few hours after birth, making further exposure to the bacteria harmless. The bacterium is an opportunistic pathogen which rarely makes its way into the bloodstream where it is associated with septicemia cases in people with neutropenia. It has different characteristics when exposed to different environmental nutrients. In the lab a SYTA plate is used...
Streptococcus pyogenes is a spherical, Gram-positive bacterium is the cause of Group A streptococcal infections. It displays streptococcal group A antigen on its cell wall. When it is cultured on blood agar plates it produces large zones of beta-hemolysis. They are catalase-negative and in ideal conditions it has an incubation period of about 1-3 days. It is an infrequent part of the skin flora. It is the cause of many important human diseases, ranging from mild superficial skin infections...
Streptococcus pneumoniae, or pneumococcus, is Gram-positive, alpha-hemolytic, bile-soluble aerotolerant, anaerobic member of the genus Streptococcus. It was recognized as a major cause of pneumonia in the late 19th century and is thus the subject of many humoral immunity studies. It causes many other types of pneumococcal infections other than pneumonia including acute sinusitis, otitis media, meningitis, bacteremia, sepsis, septic arthritis, peritonitis, cellulites, and brain abscess. It...
Streptococcus oralis is a Gram positive bacterium that grows characteristically in chains. On a Wilkins-Chalgren agar plate it will form slam white colonies. It is classified as a member of the streptococcus mitis group and is found in high numbers in the oral cavity. S. oralis produce neuraminidase and an IgA protease and cannot bind α-amylase.
Streptococcus mutans is a Gram-positive cocci, Facultative anaerobic bacterium commonly found in the human oral cavity and is a significant contributor to tooth decay. J Kilian Clarke first described the microbe in 1924. The first colonizers of the tooth surface are mainly Neisseria spp. and streptococci, including S. mutans. The pioneer species changes the local environmental conditions through growth and metabolism thus allowing more fastidious organisms to further colonize after them,...
